From COVID-19 vaccines to Moderna’s mRNA flu vaccine, using mRNA as medicine has shown promise. But before mRNA drugs can go beyond vaccines, researchers need to identify the right diseases to treat.
Articles on Moderna
Displaying 1 - 20 of 69 articles
The move signals an escalation in the agency’s efforts to interfere with established procedures for testing and approving vaccines.
Moderna recently reported the results from a phase 3 trial of its two-in-one COVID and flu vaccine.
New research confirms that COVID-19 vaccines are safe and effective at reducing the cardiovascular complications that are a hallmark of COVID-19 infection.
As the virus continues to mutate, COVID vaccines are updated. This brings us to the latest announcement about the new ‘monovalent’ vaccines.
The newly approved RSV vaccine could be rolled out by fall 2023, in time for the typical winter surge in RSV infections.
Preventive and therapeutic vaccines both train the immune system to fight disease, but they are used in different ways.
Canadian scientists have made significant contributions during the pandemic response, including vital roles in developing COVID-19 vaccines. But underfunding puts the future of science in Canada at risk.
The CDC’s endorsement of the reformulated COVID-19 booster shots represents a major step in the effort to get more Americans boosted.
The UK has become the first country to approve the shot, which targets omicron alongside the original strain of SARS-CoV-2.
It’s natural to have questions about the risks and benefits of COVID vaccines in young children. Here’s what you need to know ahead of Australia’s rollout.
Is it time for a new generation of COVID vaccines? Here’s where the research is at.
On the horizon: A new omicron-focused version of the Moderna vaccine that may offer longer protection and a stronger immune response.
Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
Boosters and vaccinating children mean we’re relying on two pharmaceutical companies to supply Australia’s COVID vaccines. That needs to change.
Moves by Moderna and BioNTech to make vaccines themselves in African countries signal that the companies aren’t considering licensing its technology to a third party for local manufacture.
New research sheds light on how Canadian researchers developed a key component of the mRNA COVID-19 vaccines but failed to share it with the world
Parents can now choose Moderna to vaccinate their children against COVID. So how effective is it, and how does it compare with Pfizer?
Fewer people reported needing to miss work after their booster, compared to their second dose.
The new omicron variant of coronavirus has a number of mutations that may require manufacturers to update vaccines. The unique attributes of mRNA vaccines make updating them fast and easy.
Top contributors
-
Professor of Medicine, University of Virginia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Microbiology, School of Medicine, University of Washington
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Law, Villanova University
-
Professor, The Children's Hospital at Westmead Clinical School and Sydney Infectious Diseases Institute, University of Sydney
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Associate Professor, School of Professional Communication, Toronto Metropolitan University
-
Professorial Fellow, University of Canberra
-
Professor of Paediatrics and vaccinologist, Royal Childrens Hospital, University of Melbourne and Murdoch Childrens Research Institute (MCRI); Associate Dean International, University of Melbourne, Murdoch Children's Research Institute
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Part-time lecturer at the Global Health & Social Medicine, Harvard University, and Lecturer at the School of Public Health, College of Health Sciences, University of Liberia
-
Paediatrician and Clinical Senior Lecturer, Children's Hospital Westmead Clinical School, University of Sydney
-
Senior Research Fellow, Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne